Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

FY2018
Financial Results Presentation

DAIICHI SANKYO CO., LTD

Sunao Manabe
President and COO

April 25, 2019

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

Agenda

1. **FY2018 Financial Results**
2. FY2019 Consolidated Forecast
3. Business Update
4. R&D Update
5. Appendix

Overview of FY2018 Results

(Bn JPY)

	FY2017 Results	FY2018 Results	YoY
Revenue	960.2	929.7	-3.2% -30.5
Cost of Sales	346.0	364.6	+18.6
SG&A Expenses	301.8	277.7	-24.2
R&D Expenses	236.0	203.7	-32.3
Operating Profit	76.3	83.7	+9.7% +7.4
Profit before Tax	81.0	85.8	+4.8
Profit attributable to owners of the Company	60.3	93.4	+55.0% +33.1

Currency Rate	USD/JPY	110.86	110.91	+0.05
	EUR/JPY	129.70	128.40	-1.30

Revenue

Decreased by 30.5 Bn JPY (Decreased by 27.3 Bn JPY excl. forex impact)

(Bn JPY)



	Positive Factors	Negative Factors
Japan		
	Lixiana +19.6	Olmetec -29.7
	Canalia +6.5	Nexium -8.3
		Inavir -7.1
		Loxonin -6.0
		(incl. impact of price revision in Japan)
	Gain on sales of transferring long-listed products +6.3	
	Daiichi Sankyo Espha (GE) +8.8	Daiichi Sankyo Healthcare -6.5
	Olmesartan AG, Rosuvastatin AG etc.	(incl. impact of change in accounting treatment)
Daiichi Sankyo, Inc. (US)		
		Welchol -20.5
		Olmesartan -10.6
		Effient -8.2
American Regent, Inc.* (US)		
	Injectafer +9.9	
Daiichi Sankyo Europe		
	Lixiana +19.2	Olmesartan -5.9

* Formerly, Luitpold Pharmaceuticals, Inc.

** Forex impact USD: +0.1, EUR : -0.9, ASCA: -2.3

Operating Profit

Increased by 7.4 Bn JPY

(Decreased by 13.2 Bn JPY excl. forex impact and special items)



(Bn JPY)

Revenue ····· **-30.5**
incl. forex impact of -3.2

Cost of Sales ····· **+2.8 (Cost increased)**
Product mix due to impact of olmesartan LOE

SG&A Expenses ····· **-14.9 (Cost decreased)**
Effect of cost reductions in US,
impact of change in accounting treatment etc.

Forex Impact ····· **-1.8 (Cost decreased)**
Cost of Sales ····· **-0.3**
SG&A Expenses ····· **-1.3**
R&D Expenses ····· **-0.2**

Special Items ····· **-22.0 (Cost decreased)**
*See next slide for details

Special Items

(Bn JPY)

	FY2017 Results		FY2018 Results		YoY
Cost of Sales	Gain on sales of fixed assets Impairment loss (Intangible)	-6.1 5.1	Impairment loss (Intangible)**	15.1	+16.1
SG&A Expenses	Restructuring costs in US Litigation fee	2.8 1.7	Gain on sales of fixed assets	-3.5	-7.9
R&D Expenses	Impairment loss (Intangible)*	30.2			-30.2
Total		33.6		11.6	-22.0

*CL-108 and others

**Zelboraf and Movantik

- : Cost decreased items

Booked in Q4

Special items :
Items having a transitory and material impact on operating profit are defined as "Special items".
Specifically, gains and losses related to: sale of fixed assets, restructuring, impairment, litigation, etc. amounting to 1 billion JPY or more are defined as "Special items".

Profit Attributable to Owners of the Company

Increased by 33.1 Bn JPY



(Bn JPY)

Financial Income/ Expenses etc. ····· +2.6 (Cost increased)

Deterioration of forex gains/ losses

Income Taxes etc. ····· -28.8 (Cost decreased)

Increase in DTA attributable to future expected taxable income increase due to DS-8201 strategic collaboration

	FY2017	FY2018	YoY
Profit before Tax	81.0	85.8	+4.8
Income Taxes etc.	21.2	-7.6	-28.8
Tax rate	26.2%	-8.8%	-35.0%

Non-Controlling Interests ····· +0.5 (Cost increased)

Revenue: Major Business Units (incl. Forex Impact)

(Bn JPY)

	FY2017 Results	FY2018 Results	YoY
Japan	**540.0**	**523.3**	**-16.7**
Daiichi Sankyo Healthcare	**72.9**	**66.4**	**-6.5**
Daiichi Sankyo, Inc.	**74.8**	**36.3**	**-38.5**
Olmesartan	21.3	10.7	-10.6
Welchol	33.9	13.4	-20.5
Effient	10.7	2.4	-8.2
Savaysa	2.2	2.3	+0.1
Movantik	4.7	4.2	-0.5
American Regent, Inc.	**105.4**	**117.8**	**+12.4**
Venofer	31.0	28.9	-2.0
Injectafer	34.3	44.2	+9.9
GE injectables	37.1	38.5	+1.5
Daiichi Sankyo Europe	**79.4**	**88.6**	**+9.1**
Olmesartan	33.5	27.4	-6.1
Efient	8.0	5.7	-2.3
Lixiana	27.0	45.8	+18.8
ASCA (Asia, South and Central America)	**80.4**	**87.7**	**+7.3**

Currency Rate	USD/JPY	110.86	110.91	+0.05
	EUR/JPY	129.70	128.40	-1.30

Revenue: Major Products in Japan

(Bn JPY)

		FY2017 Results	FY2018 Results	YoY
Nexium	ulcer treatment	**86.5**	**78.3**	**-8.3**
Lixiana	anticoagulant	**45.3**	**64.9**	**+19.6**
Memary	Alzheimer's disease treatment	**48.6**	**50.2**	**+1.7**
Loxonin	anti-inflammatory analgesic	**36.5**	**30.5**	**-6.0**
Pralia	treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	**23.2**	**27.4**	**+4.2**
Tenelia	type 2 diabetes mellitus treatment	**26.3**	**25.3**	**-1.0**
Inavir	anti-influenza treatment	**25.3**	**18.2**	**-7.1**
Olmetec	antihypertensive agent	**44.6**	**14.9**	**-29.7**
Ranmark	treatment for bone complications caused by bone metastases from tumors	**15.4**	**16.4**	**+1.0**
Efient	antiplatelet agent	**12.8**	**13.9**	**+1.1**
Rezaltas	antihypertensive agent	**16.8**	**15.5**	**-1.3**
Urief	treatment for dysuria	**11.1**	**10.3**	**-0.9**
Omnipaque	contrast medium	**14.0**	**12.0**	**-2.0**
Canalia	type 2 diabetes mellitus treatment	**2.7**	**9.2**	**+6.5**
Vimpat	anti-epileptic agent	**2.6**	**6.6**	**+3.9**

1 FY2018 Financial Results

2 **FY2019 Consolidated Forecast**

3 Business Update

4 R&D Update

5 Appendix

FY2019 Consolidated Forecast

(Bn JPY)

	FY2018 Results	FY2019 Forecast	YoY
Revenue	929.7	940.0	+1.1% +10.3
Cost of Sales	364.6	330.0	-34.6
SG&A Expenses	277.7	285.0	+7.3
R&D Expenses	203.7	225.0	+21.3
Operating Profit	83.7	100.0	+19.5% +16.3
Profit before Tax	85.8	100.0	+14.2
Profit attributable to owners of the Company	93.4	72.0	-22.9% -21.4

Currency Rate	USD/JPY	110.91	110.00
	EUR/JPY	128.40	130.00

FY2019 Consolidated Forecast

(Bn JPY)

	FY2018 Results (excl. special items)	FY2019 Forecast	YoY
Revenue	929.7	940.0	+1.1% +10.3
Cost of Sales	349.5	330.0	-19.5
SG&A Expenses	281.2	285.0	+3.8
R&D Expenses	203.7	225.0	+21.3
Operating Profit	95.3	100.0	+4.9% +4.7

Currency Rate	USD/JPY	110.91	110.00
	EUR/JPY	128.40	130.00

- Deferred revenue for DS-8201 strategic collaboration upfront payment +10.0
- Gain on sales of Takatsuki Plant transfer -19.0
- Gain on sales of Nihonbashi building -10.6
- Costs increase for the establishment of the oncology business structure
- Increase in R&D investments to DS-8201

*Regarding the impact of DS-8201 strategic collaboration, only deferred revenue for upfront payment is included in FY2019 forecast

1 FY2018 Financial Results

2 FY2019 Consolidated Forecast

3 **Business Update**

4 R&D Update

5 Appendix

Daiichi-Sankyo

Edoxaban

Japan Business

Streamlining of Assets

Shareholder Returns

Edoxaban

Japan Business

Streamlining of Assets

Shareholder Returns

Lixiana: Growth in Japan

Sales

Daiichi-Sankyo

- FY2018 Q4: No.1 sales share (33.2%)
- FY2018 Revenue Results : 64.9 Bn JPY (YoY +19.6 Bn JPY)
- FY2019 Revenue Forecast: 77.0 Bn JPY (YoY +12.1 Bn JPY)



Edoxaban: Growth in Each Country

Volume

Daiichi-Sankyo

- **Steady growth in each country**
- **FY2018 Global Revenue Results : 117.7 Bn JPY (YoY +40.6 Bn JPY)**
- **FY2019 Global Revenue Forecast: 149.0 Bn JPY (YoY +31.3 Bn JPY)**



China: Approved in Dec. 2018

Calculated based on MIDAS Data: FY2014 Q4 - FY2018 Q3

Edoxaban: Life Cycle Management

EDOSURE
Edoxaban Clinical Research Program
more than 10 studies, more than 100,000 patients worldwide

Daiichi-Sankyo

◆ **Conducting randomized controlled trials in various clinical settings in AF and VTE to expand the scientific knowledge**

Study Name	Clinical Setting (Comparator)	Primary Completion
ENSURE-AF	Cardioversion (enoxaparin/ warfarin)	Presented at ESC 2016
ENTRUST-AF PCI	PCI (warfarin)	June 2019
ELIMINATE-AF	Cardiac ablation (warfarin)	Presented at EHRA* 2019
ENVISAGE-TAVI AF	Transcatheter aortic valve implantation (warfarin)	November 2020
ELDERCARE-AF	80 years or older who are ineligible for current OAC therapy (placebo)	December 2019
Hokusai VTE CANCER	VTE associated with cancer (dalteparin)	Presented at ASH 2017

FY2018 Results

Patient enrollment progressed as planned
- Data will be disclosed in FY2019

Late-breaking data presented at EHRA* in Mar. 2019
- Confirmed the efficacy and safety of edoxaban in the treatment of patients undergoing catheter ablation of AF

*European Heart Rhythm Association

Edoxaban: Life Cycle Management

EDOSURE
Edoxaban Clinical Research Program
more than 10 studies, more than 100,000 patients worldwide

Daiichi-Sankyo

- **Conducting non-interventional studies and registries to generate real-world data to expand the scientific knowledge**

Study Name	Clinical Setting	FY2018 Results
ETNA-AF Global	Edoxaban Treatment in routine clinical practice in AF	Baseline data presented at ESC in Aug. 2018 ➢ One-year follow-up data will be presented during FY2019
ETNA-VTE Global	Edoxaban Treatment in routine clinical practice in VTE	
EMIT-AF/VTE	Edoxaban Management In diagnostic and Therapeutic procedures–AF/VTE	Data presented at EHRA in Mar. 2019 ➢ Confirmed the efficacy and safety of periprocedural edoxaban management in clinical practice
PREFER in AF Prolongation	Prolongation PREFER in AF, European Registry	
ANAFIE	All Nippon AF In Elderly Registry (in more than 75 years in Japan)	Baseline data presented at Japanese College of Cardiology (JCC) in Sep. 2018
Cancer–VTE Registry Venous Thromboembolism in Cancer Patients	Multicenter Prospective Registry in VTE patients associated with cancer	

Edoxaban

Japan Business

Streamlining of Assets

Shareholder Returns

Japan Business: New Products Launch

◆ Tarlige (mirogabalin): Launched in Apr. 2019

- MOA: α2δ ligand
- Indication: peripheral neuropathic pain

◆ Minnebro (esaxerenone): Launch in May. 2019

- MOA: mineralocorticoid blocker
- Indication: hypertension

Edoxaban

Japan Business

Streamlining of Assets

Shareholder Returns

Streamlining of Assets

		FY2016 Results	FY2017 Results	FY2018 Results	Total
Reduce cross-shareholding shares	Number of stock brands	**14** brands	**9** brands	**10** brands	**33** brands
	Sales proceeds	**17.3** Bn JPY	**14.4** Bn JPY	**14.3** Bn JPY	**46.0** Bn JPY
	Gain on sales*	9.3 Bn JPY	9.8 Bn JPY	10.6 Bn JPY	29.7 Bn JPY
Sale of properties	Sales proceeds	**3.2** Bn JPY	**10.7** Bn JPY	**11.0** Bn JPY	**25.0** Bn JPY
	Gain on sales	0.8 Bn JPY	7.6 Bn JPY	9.0 Bn JPY	17.5 Bn JPY
Gain on sales of business transfer	Gain on sales	-	-	(transferring long-listed products) **6.3** Bn JPY	**6.3** Bn JPY

* Booked in other comprehensive income

Gain on sales of Takatsuki Plant transfer (19.0 Bn JPY) and Nihonbashi building (10.6 Bn JPY) will be booked in FY2019

Edoxaban

Japan Business

Streamlining of Assets

Shareholder Returns

Shareholder Returns

Shareholder Returns Policy: FY2016 - FY2022

	FY2016 Results	FY2017 Results	FY2018 Results	FY2019 Plan
Dividend	**70 JPY**	**70 JPY**	**70 JPY**	**70 JPY**
Acquisition of own shares	**50.0 Bn JPY**	**50.0 Bn JPY**	**-**	**Flexible**
Total return ratio*	**180.7%**	**159.1%**	**48.5%**	**-**
	114.8%			

*Total return ratio = (Dividends + Total acquisition costs of own shares) / Profit attributable to owners of the company

1 FY2018 Financial Results

2 FY2019 Consolidated Forecast

3 Business Update

4 **R&D Update**

5 Appendix

Daiichi-Sankyo

FY2018 Results

Progress of DS-8201

SAKIGAKE Designation of DS-3201

DS-1647 (G47Δ) P2 IIS Study Result

New Phase 3 Study of Mirogabalin

Upcoming Milestones

ASCO IR Events

FY2018 Results

Progress of DS-8201

SAKIGAKE Designation of DS-3201

DS-1647 (G47Δ) P2 IIS Study Result

New Phase 3 Study of Mirogabalin

Upcoming Milestones

ASCO IR Events

DS-8201: FY2018 Results



Other Oncology: FY2018 Results



BCL: B-cell lymphoma, NSCLC: non-small-cell lung cancer, TGCT: tenosynovial giant cell tumor

Specialty Medicine: FY2018 Results

Fiscal year		FY2018											
Month		4	5	6	7	8	9	10	11	12	1	2	3
Edoxaban	AF/VTE									Approved	China		
Mirogabalin	PNP									Japan		Approved	
	CNP												Started P3 study
Esaxerenone	Hyper-tension									Japan		Approved	
Laninamivir (nebulizer)	Influenza				JP NDA								

AF: atrial fibrillation, CNP: central neuropathic pain, PNP: peripheral neuropathic pain, VTE: venous thromboembolism

FY2018 Results

Progress of DS-8201

SAKIGAKE Designation of DS-3201

DS-1647 (G47Δ) P2 IIS Study Result

New Phase 3 Study of Mirogabalin

Upcoming Milestones

ASCO IR Events

DS-8201: Study Plan

As of April 2019

Daiichi-Sankyo



HER2 Positive mBreast Cancer 3rd-line Application Plan

Daiichi-Sankyo

Preparation for BLA submission is progressing steadily

US	Japan	EU
BLA submission 1H FY2019	NDA submission 2H FY2019	MAA submission 1H FY2020
Estimated Review Period: 6M after acceptance of the application	Estimated Review Period: Maximum 12M after application	Estimated Review Period: 12M after application
Fast-track status		
BTD designation		

BTD: Breakthrough therapy designation

Underlined in red: new or updated from FY2018 Q3

HER2 Positive BC Treatment Flow and Ongoing DS-8201 Studies



* JP/US/EU5, DS estimation, **JP/US/EU5; Source: CancerMPact®, Kantar Health/ Synix inc. (Strict diversion of confidential information)

HER2 Low(HR+) BC Treatment Flow and Ongoing DS-8201 Study



* JP/US/EU5, DS estimation, **JP/US/EU5; Source: CancerMPact®, Kantar Health/ Synix inc. (Strict diversion of confidential information)

HER2 Low(HR-) BC Treatment Flow and Ongoing DS-8201 Study



* JP/US/EU5, DS estimation, **JP/US/EU5; Source: CancerMPact®, Kantar Health/ Synix inc. (Strict diversion of confidential information)

HER2 Expressing GC Treatment Flow and Ongoing DS-8201 Study



* JP/US/EU5, DS estimation, **JP/US/EU5; Source: CancerMPact®, Kantar Health/ Synix inc. (Strict diversion of confidential information)

Gastric Cancer Patients in West

West (US+EU5) GC patients are larger than Japan



JP/US/EU5; Source: CancerMPact®, Kantar Health/ Synix inc.（Strict diversion of confidential information）

HER2 Expressing GC US/EU P2 Study Design

- **Historical data of comparable drug suggests East and West gastric cancer patients may have different efficacy**
- **Planned to start the study from Q2 FY2019**



Study patients	HER2 positive gastric and gastroesophageal junction cancer
Primary endpoint	ORR
Secondary endpoint	PFS, OS
CTG/JAPIC	TBD

FY2018 Results

Progress of DS-8201

SAKIGAKE Designation of DS-3201

DS-1647 (G47Δ) P2 IIS Study Result

New Phase 3 Study of Mirogabalin

Upcoming Milestones

ASCO IR Events

SAKIGAKE Designation: DS-3201 PTCL

- Potential first-in-class **EZH1/2 dual inhibitor**
- Received SAKIGAKE Designation for **relapsed/refractory peripheral T-cell lymphoma (PTCL)** treatment based on the preliminary result of Phase 1 Non-Hodgkin lymphomas trial including PTCLs

Preliminary results in relapsed or refractory Non-Hodgkin Lymphoma



ASH2017

PTCL

- Non-Hodgkin lymphoma arising from T cells
- Tend to be aggressive and associated with poor prognosis, particularly for relapsed disease
- **High unmet medical needs** (very few treatment options)

FY2018 Results

Progress of DS-8201

SAKIGAKE Designation of DS-3201

DS-1647 (G47Δ) P2 IIS Study Result

New Phase 3 Study of Mirogabalin

Upcoming Milestones

ASCO IR Events

DS-1647 (G47Δ) Oncolytic Virus

G47Δ: Innovative cancer therapy with most advanced oncolytic virus

- Third-generation oncolytic virus: herpes simplex virus type 1 (HSV-1) was modified to grow exclusively in cancer cells by genetic recombination
- Developing this treatment for various solid cancers, including Glioblastoma, in collaboration with Professor Tomoki Todo of the Institute of Medical Sciences of the University of Tokyo

Synosis of Phase 2 IIS Trial (glioblastoma multiforme)	
Objective	Evaluating the efficacy and safety of G47Δ in patients with glioblastoma with residual or recurrent tumors after radiation alone or radiation plus temozolomide
Design	Open-label study (no control group)
Primary endpoint	1 year survival rate
Secondary endpoints	Overall survival; Progression-free survival; Tumor response; Safety
Case	Target 30 cases (interim analysis in 13 cases)
Dosage and administration	Stereotactic brain surgery for intratumoral administration, up to 6 doses

Interim Analysis Results of Phase 2 Clinical Trials (IIS)

- **Interim analysis lead to stop study early after confirming efficacy**
- **Professor Todo presented the results at AACR-JCA**
- **Planning to submit NDA in Japan in 1H FY2019 (SAKIGAKE Designation)**

Efficacy

Primary endpoint

- **1 year survival rate: 92.3%** (12/13 cases survived)

Secondary endpoint

- PFS: 8.6 months
- Tumor response : SD for all 4 patients at the end of follow-up

Safety

Good safety profile is suggested

- Side effect leading prolonged hospitalization: 2/16 (12.5%)
- AEs leading to discontinue treatment: 1/16 (6.3%)

Glioblastoma

- Gliomas represent about a quarter of brain tumors
- Glioblastoma is the most common and most aggressive type of glioma
- The 5-yr survival rate with standard therapy is about 10% and healing is extremely difficult
- About 1,000 patients per year in Japan

FY2018 Results

Progress of DS-8201

SAKIGAKE Designation of DS-3201

DS-1647 (G47Δ) P2 IIS Study Result

New Phase 3 Study of Mirogabalin

Upcoming Milestones

ASCO IR Events

Mirogabalin: Life Cycle Management

Started P3 study for indication expansion

	Classification	Diseases	Status
Neuropathic Pain 	Peripheral	・Diabetic peripheral neuropathic pain ・Postherpetic neuralgia, etc.	Approved
	Central	・**Neuropathic pain after spinal cord injury** ・Pain related to Parkinson's disease ・Post stroke pain, etc.	**P3 started**

Double blind phase (14W) N=274

Mirogabalin

Placebo

Open-label extension phase (52W) N=180

Mirogabalin

Target	**Central neuropathic pain (neuropathic pain after spinal cord injury, etc.)**
Primary endpoint	Change in the weekly average daily pain score from baseline to Week 14
CTG/JAPIC	NCT03901352/JapicCTI-194653

FY2018 Results

Progress of DS-8201

SAKIGAKE Designation of DS-3201

DS-1647 (G47Δ) P2 IIS Study Result

New Phase 3 Study of Mirogabalin

Upcoming Milestones

ASCO IR Events

Upcoming Milestones: ASCO

ASCO abstract release: 5/15, 5pm (ET)

U3-1402		EGFRm NSCLC P1 Study ASCO: **oral presentation on May 31, 2019**
DS-1062		NSCLC P1 Study ASCO: **poster presentation on June 2, 2019**
DS-1001		Glioma **ASCO: oral presentation on June 3, 2019**

Underlined in red: new or updated from FY2018 Q3

ASCO IR Events

On-site conference

Date	June 2 (Sunday) 5:00-8:00 pm CDT (planned)
Speaker	Sunao Manabe, COO Antoine Yver, Oncology R&D Head
Contents	About presentation in ASCO * This content will be distributed on-demand at a later date

Conference call

Date	June 3 (Monday) 9:00-10:00 pm JST
Speaker	Sunao Manabe, COO Antoine Yver, Oncology R&D Head
Contents	About presentation in ASCO * This content will be distributed on-demand at a later date

Upcoming Milestones

Daiichi-Sankyo

DS-8201	Breast	HER2 positive mBC 3rd-line BLA submission in 1H FY2019 (US) **NDA submission in 2H FY2019 (Japan)** DESTINY-BREAST01 (Pivotal P2 study) **SABCS: December 2019 (planned)**
Quizartinib	AML	Relapsed/refractory AML **ODAC May 14, 2019** FDA PDUFA **August 25, 2019 (3M delay)**
Pexidartinib	TGCT	Tenosynovial giant cell tumor **ODAC May 14, 2019** FDA PDUFA August 3, 2019
DS-1647 (G47Δ)	GBM	Glioblastoma multiforme **NDA submission in 1H FY2019 (Japan)**

ODAC: Oncology Drug Advisory Committee

Underlined in red: new or updated from FY2018 Q3

1 FY2018 Financial Results

2 FY2019 Consolidated Forecast

3 Business Update

4 R&D Update

5 **Appendix**

FY2019 R&D Milestones

As of April 2019

Daiichi-Sankyo

Project	Indications and Studies	FY2018	FY2019			
		Q4	Q1	Q2	Q3	Q4
DS-8201	P2 pivotal: BC (HER2 positive post T-DM1)		US submission		JP Submission	
	P2: GC (US/EU)			Study start		
	P1b: BC/NSCLC (with pembrolizumab)		→	→	Study start	
	P1b: solid tumor (with avelumab)		→	→	Study start	
Quizartinib	P3: relapsed/refractory AML			US approval		
Pexidartinib	P3: TGCT (US/EU)	EU Submitted		US approval		
DS-1647	IIS: glioblastoma multiforme (JP)	TLR	Submission			
DS-1205	P1: NSCLC with osimertinib (Asia)		Study started			
Mirogabalin	P3: PNP (JP)	Approved	Launched			
	P3: central neuropathic pain (JP/Asia)	Study started				
Esaxerenone	P3: hypertension (JP)	Approved	Launch			
Laninamivir	P3: influenza (nebulizer formulation) (JP)			Approval		

AML: acute myeloid leukemia, EGFRm: EGFR mutation, NSCLC: non-small cell lung cancer, PNP: peripheral neuropathic pain, TGCT: tenosynovial giant cell tumor, TLR: top line results

Underlined in red: new or updated from FY2018 Q3 **Blue: achieved**

Major R&D Pipeline (Oncology)

As of April 2019

Daiichi-Sankyo

	Generic name/Project number (drug efficacy/mechanism of action)	Target Indication	Region	Stage
ADC Franchise	DS-8201 (anti-HER2 ADC)	BC (HER2 positive post T-DM1)	JP/US/EU/Asia	Phase 2 ★ / Phase 3
		BC (HER2 positive vs T-DM1)	JP/US/EU/Asia	Phase 3
		BC (HER2 low)	JP/US/EU/Asia	Phase 3
		GC (HER2 expressing post trastuzumab)	JP/Asia	Phase 2 ★
		CRC	JP/US/EU	Phase 2
		NSCLC	JP/US/EU	Phase 2
		BC and bladder cancer (with nivolumab)	US/EU	Phase 1
	U3-1402 (anti-HER3 ADC)	BC	JP/US	Phase 1
		NSCLC	US	Phase 1
	DS-1062 (anti-TROP2 ADC)	NSCLC	JP/US	Phase 1
AML/HEM Franchise	Quizartinib/AC220 (FLT3 inhibitor)	AML (relapsed/refractory)	JP/US/EU/Asia	NDA/BLA
		AML (1st line)	JP/US/EU/Asia	Phase 3
	DS-3032 (MDM2 inhibitor)	Solid tumor	JP/US	Phase 1
		AML	JP/US	Phase 1
	DS-3201 (EZH1/2 inhibitor)	PTCL	JP	Phase 1
		ATL/L	JP	Phase 1
		AML、ALL	US	Phase 1
	PLX2853 (BRD4 inhibitor)	AML, solid cancer	US	Phase 1
	DS-1001 (IDH1m inhibitor)	Glioma	JP	Phase 1
	Axi-Cel® (anti-CD19 CAR-T cells)	BCL	JP	Phase 2 ★
Breakthrough Science	Pexidartinib (CSF-1/KIT/FLT3 inhibitor)	TGCT	US/EU	NDA/BLA
	DS-1647 (G47Δ virus)	Glioblastoma multiforme	JP	Phase 2 ★ / Phase 3
	DS-1205 (AXL inhibitor)	NSCLC [with osimertinib (Asia) gefitinib (JP)]	JP/Asia	Phase 1

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B-cell lymphoma, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma, TGCT: tenosynovial giant cell tumor

★: Projects in the field of oncology which are planned for registration application based on the results of P2 studies, designated as breakthrough therapy (FDA)/SAKIGAKE (JP)

Major R&D Pipeline (SM/Vaccination)

As of April 2019

Daiichi-Sankyo

	Generic Name/Project Code Number (Drug Efficacy/Mechanism of Action)	Target Indications	Region	Stage
Specialty Medicine (SM)	Edoxaban / DU-176b (Fxa-inhibitor)	Very elderly patients AF	JP	Phase 3
	Prasugrel / CS-747 (anti-platelet agent)	Ischemic stroke	JP	Phase 3
	Esaxerenone / CS-3150 (MR-antagonist)	Diabetic nephropathy	JP	Phase 3
	DS-1040 (TAFIa inhibitor)	Acute ischemic stroke, acute pulmonary embolism	JP/US/EU	Phase 1
	DS-2330 (hyperphosphatemia treatment)	Hyperphosphatemia in chronic kidney disease	-	Phase 1
	Mirogabalin (α2δ ligand)	Central neuropathic pain	JP/Asia	Phase 3
	Laninamivir / CS-8958 (neuraminidase inhibitor)	Influenza	JP	NDA
	DS-5141 (ENA-oligonucleotide)	DMD	JP	Phase 2
	DS-1211 (TNAP inhibitor)	Inhibition of ectopic calcification	US	Phase 1
Vaccination	VN-0107/MEDI3250 (live attenuated influenza vaccine)	Prophylaxis of seasonal influenza	JP	NDA
	VN-0105 (DPT-IPV/Hib)	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib)	JP	Phase 3
	VN-0102/JVC-001 (Measles-mumps-rubella vaccine)	For measles, mumps, and rubella Prophylaxis	JP	Phase 2

AF: atrial fibrillation, DMD: Duchenne muscular dystrophy
designated as breakthrough therapy (FDA)/SAKIGAKE (JP)

Out-licensing Projects

As of Apr 2019

Daiichi-Sankyo

	Pre-clinical	Phase 1	Phase 2
Oncology		■ **PLX7486** （Solid tumor / FMS/TRK inhibitor） ■ **PLX8394** （Solid tumor / BRAF inhibitor） ■ **PLX9486** （Solid tumor (gastrointestinal stromal tumor) / KIT inhibitor）	
Specialty Medicine	■ **DS-1515** （Inflammatory disease / PI3Kδ inhibitor） ■ **DS-1039** （Cystic fibrosis / new MOA （CFTR independent fluid secretion）） ■ **ASB29609** （Circadian rhythm sleep-wake disorders / 5-HT5A receptor agonist）	■ **DS-2969** （Clostridium difficile infection / GyrB inhibitor） ■ **DS-1093** （inflammatory bowel disease (IBD) / HIF-PH inhibitor） ■ **DS-7080** (AMD / angiogenesis inhibitor) ■ **DS-1501: US/EU (other than JP)** （Osteoporosis / anti Siglec-15 antibody）	■ **Laninamivir** (CS-8958/anti-influenza / out-licensing with Vaxart Inc)

Status of Accelerated Development Support Program

Project (indication)	Japan	US	Europe
DS-8201 (BC 3rd line)		Fast track Breakthrough therapy	
DS-8201 (GC 2nd line)	SAKIGAKE		
Quizartinib (AML)	Orphan drug	Fast track Breakthrough therapy Orphan drug	Orphan drug
DS-3201 (PTCL)	SAKIGAKE		
Axi-Cel® (BCL)	Orphan drug		
Pexidartinib (TGCT)		Breakthrough therapy Orphan drug Priority review	Orphan drug
DS-1647(G47Δ) Glioblastoma multiforme	SAKIGAKE		
DS-5141 (DMD)	SAKIGAKE		

AML: acute myeloid leukemia, BCL: B-cell lymphoma, DMD: Duchenne muscular dystrophy, PTCL: peripheral T-cell lymphoma, TGCT: tenosynovial giant cell tumor

Listing of abbreviations

Abbreviations	English	Implications
BTD	Breakthrough therapy designation	Designation of innovative therapeutics
CR	Complete response	Complete response (complete resolution of cancer)
DCR	Disease control rate	Disease control rate (percentage of patients with controlled disease status)
DLT	Dose limiting toxicity	Dose-limiting toxicities (toxicities that may explain the inability to escalate doses)
DOR	Duration of response	Duration of response (duration of response)
EGFR	Epidermal growth factor receptor	Epidermal growth factor receptor
MTD	Maximum tolerated dose	Maximum tolerated dose (dose with intolerable toxicity)
ORR	Overall response rate Objective response rate	Overall response rate (expressed as the proportion of patients who responded to treatment and the sum of CR and PR)
OS	Overall survival	Overall survival (time from start of treatment to death)
PD	Progress disease	Disease progression (worsening disease despite treatment)
PFS	Progression-free survival	Progression-free survival (without cancer progression)
PR	Partial response	Partial response (a reduction in the size of the cancer by 30% or more that lasts for 4 weeks)
SD	Stable disease	The size of the cancer is almost unchanged before and after treatment

Inquiries about this document

Daiichi Sankyo Co., Ltd.

Corporate Communications Dept.

TEL:+81-3-6225-1126

Email: DaiichiSankyoIR@daiichisankyo.co.jp